| Erratum à Bictégravir/emtricitabine/ténofovir alafénamide (B/F/TAF) chez les PVVIH pré-traitées et présentant des symptômes de dépression, d'anxiété ou d'insomnie (DAI) dans le … S Esser, B Trottier, A Antinori, E Hila, A Antela, ET Tigen, M Boffito, ... Médecine et Maladies Infectieuses Formation, 2024 | | 2024 |
| Implementation of long‐acting cabotegravir and rilpivirine: primary results from the perspective of staff study participants in the Cabotegravir And Rilpivirine Implementation … CA Gutner, L Hocqueloux, C Jonsson‐Oldenbüttel, L Vandekerckhove, ... Journal of the International AIDS Society 27 (7), e26243, 2024 | | 2024 |
| Clinical Outcomes of Integrase Strand Transfer Inhibitors Containing Antiretroviral Therapy in HIV-2: A Narrative Review WJ Boschloo, BJ van Welzen Infectious Diseases and Therapy, 1-15, 2024 | | 2024 |
| Underlying Neural Mechanisms of Cognitive Improvement in Fronto-striatal Response Inhibition in People Living with HIV Switching Off Efavirenz: A Randomized Controlled BOLD … PGA Oomen, CS Hakkers, JE Arends, GEL van der Berk, P Pas, ... Infectious Diseases and Therapy, 1-16, 2024 | | 2024 |
| Dolutegravir/Lamivudine Is Noninferior to Continuing Dolutegravir-and Non-Dolutegravir-Based Triple-Drug Antiretroviral Therapy in Virologically Suppressed People With Human … M Vasylyev, FWNM Wit, CCE Jordans, R Soetekouw, SFL van Lelyveld, ... Open forum infectious diseases 11 (4), ofae160, 2024 | | 2024 |
| Twelve‐month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV: Real‐world insights from BICSTaR cohorts S Esser, J Brunetta, A Inciarte, I Levy, A D'Arminio Monforte, JS Lambert, ... HIV medicine 25 (4), 440-453, 2024 | 6 | 2024 |
| Reply to Buzón-Martín and Troya BJ Van Welzen, D Burger, AMJ Wensing Clinical Infectious Diseases, ciae142, 2024 | | 2024 |
| Dynamics of Low-Level Viremia and Immune Activation after Switching to a Darunavir-Based Regimen AJ Stam, NVEJ Buchholtz, WFW Bierman, R van Crevel, AIM Hoepelman, ... Viruses 16 (2), 182, 2024 | 1 | 2024 |
| Virological failure after switch to long-acting cabotegravir and rilpivirine injectable therapy: an in-depth analysis BJ van Welzen, SFL Van Lelyveld, G Ter Beest, JH Gisolf, SE Geerlings, ... Clinical Infectious Diseases, ciae016, 2024 | 16 | 2024 |
| Patrick GA Oomen Charlotte S. Hakkers Joop E. Arends Guido EL van der Berk P Pas, AIM Hoepelman, BJ van Welzen, S du Plessis HIV: OPTIMIZING TREATMENT AND MONITORING BEYOND VIROLOGIC SUPPRESSION, 123, 2024 | | 2024 |
| REAL-WORLD EFFECTIVENESS AND TOLERABILITY OF SWITCHING TO DORAVIRINE-BASED ANTIRETROVIRAL THERAPY IN PEOPLE WITH HIV: A NATIONWIDE MATCHED COHORT STUDY PGA Oomen, FWNM Wit, K Brinkman, SME Vrouenraets, T Mudrikova, ... HIV: OPTIMIZING TREATMENT AND MONITORING BEYOND VIROLOGIC SUPPRESSION, 27, 2024 | | 2024 |
| Failure following switch from long-term suppressive oral ART to long-acting cabotegravir/rilpivirine injections BJ Van Welzen, S van Lelyveld, G ter Beest, SE Geerlings, J Prins, ... HIV MEDICINE 24, 368-369, 2023 | 2 | 2023 |
| Efficacy, safety and implementation outcomes of Cabotegravir plus Rilpivirine long-acting by country in the Cabotegravir and rilpivirine implementation study in European … C Jonsson-Oldenbuettel, J Ghosn, JO Sierra, M van der Valk, T Lutz, ... HIV MEDICINE 24, 193-195, 2023 | | 2023 |
| Cabotegravir plus Rilpivirine longacting efficacy and safety outcomes by sex at birth, age and race: A subgroup analysis of the CARISEL study J Ghosn, L Hocqueloux, MJ Crusells-Canales, L Belkhir, ... HIV MEDICINE 24, 187-188, 2023 | | 2023 |
| Real-world effectiveness and tolerability of doravirine-based antiretroviral therapy in people with HIV: A nationwide matched cohort study PGA Oomen, F Wit, K Brinkman, SME Vrouenraets, T Mudrikova, ... HIV MEDICINE 24, 97-98, 2023 | | 2023 |
| 1611. Real-World Effectiveness and Tolerability of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Treatment-Experienced People With HIV and a History of … B Trottier, F Bonnet, M Garcia-Deltoro, M Andreoni, M Boffito, ... Open Forum Infectious Diseases 10 (Supplement_2), ofad500. 1446, 2023 | | 2023 |
| Real-World Effectiveness and Tolerability of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Treatment-Experienced (TE) People with HIV with a History of CKD: TH … A Rieke, J De Wet, V Esposito, A Silva-Klug, I Levy, JS Lambert, M Boffito, ... Journal of the American Society of Nephrology 34 (11S), 392-393, 2023 | | 2023 |
| Estimated glomerular filtration rate, albuminuria, and adverse outcomes: an individual-participant data meta-analysis LJ Appel, M Grams, M Woodward, K Harris, H Arima, J Chalmers, ... Jama 330 (13), 1266-1277, 2023 | 41 | 2023 |
| Integrated analysis of viral blips, residual viremia, and associated factors in people with HIV: Results from a retrospective cohort study PGA Oomen, S Dijkstra, LM Hofstra, MM Nijhuis, A Verbon, T Mudrikova, ... Journal of Medical Virology 95 (10), e29178, 2023 | 2 | 2023 |
| Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study D Razavi-Shearer, I Gamkrelidze, C Pan, J Jia, T Berg, R Gray, YS Lim, ... The Lancet Gastroenterology & Hepatology 8 (10), 879-907, 2023 | 95 | 2023 |
